Literature DB >> 26190162

BRAF (V600E) mutation in isthmic malignant thyroid nodules.

A Campennì1, L Giovanella2, A Alibrandi3, M Siracusa4, R M Ruggeri5, S Baldari4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26190162     DOI： 10.1111/cen.12858

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  4 in total

1.  Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.

Authors:  Alfredo Campennì; Ernesto Amato; Riccardo Laudicella; Angela Alibrandi; Davide Cardile; Salvatore Antonio Pignata; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Lucrezia Auditore; Sergio Baldari
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

Review 2.  Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target.

Authors:  Maria Trovato; Alfredo Campennì; Salvatore Giovinazzo; Massimiliano Siracusa; Rosaria Maddalena Ruggeri
Journal:  Biomark Insights       Date:  2017-03-30

3.  Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients.

Authors:  Alfredo Campennì; Luca Giovanella; Salvatore Antonio Pignata; Antonio Vento; Angela Alibrandi; Letterio Sturiale; Riccardo Laudicella; Alessio Danilo Comis; Rossella Filice; Giuseppe Giuffrida; Maria Elena Stipo; Salvatore Giovinazzo; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Sergio Baldari
Journal:  Oncotarget       Date:  2018-04-03

4.  Thyroid papillary carcinoma with the 'snowstorm appearance': a clinicopathological analysis of three cases.

Authors:  Ruixue Lei; Haijun Yang
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.